Gilead Sciences Places $120M Bet on a Jounce Therapeutics Cancer Drug

Gilead Sciences is opening up its checkbook yet again to add another cancer therapy to its pipeline, this time committing $120 million to Jounce Therapeutics for rights to an antibody drug approaching clinical testing. The Jounce (NASDAQ: JNCE) drug, JTX-1811, is intended to selectively deplete regulatory T cells—the type of immune cells that suppress the […]

Click to view original post